Skip to content
Adam Torkildson – Lifestyle
Author:
Transgene S.A.
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
April 2, 2026
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
March 26, 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
March 24, 2026
←
Previous Page
1
2